CTT Pharmaceutical Holdings Inc. (CTTH)

Overview

CTT Pharmaceutical Holdings, Inc., originally known as Mindesta Inc. before its name change in July 2015, is a pioneering company in the pharmaceutical industry with its headquarters situated in Ottawa, Canada. The company is at the forefront of developing innovative oral drug delivery systems, particularly focusing on the management and treatment of pain. It specializes in creating fast dissolving drug delivery systems that stand as a testament to its commitment to revolutionizing patient care and medication administration methods.

Products and Services

• Advanced Oral Delivery Thin Wafers:

CTT Pharmaceutical’s flagship technology encompasses the development and commercialization of advanced oral delivery thin wafers. These wafers represent a significant breakthrough in drug delivery systems, being designed to dissolve quickly in the mouth. Infused with either natural and/or synthetic cannabis extracts, these thin wafers offer an effective, smoke-free, and convenient alternative for cannabis intake, catering to both medicinal and therapeutic needs. The versatility in the formulation allows for the delivery of a wide range of treatments, ensuring a broad market application.

• Patented Orally Administrable Wafer:

The cornerstone of CTT Pharmaceutical’s product line is its patented orally administrable wafer, which is composed of at least one physiologically acceptable film-forming agent. This proprietary wafer is the embodiment of the company’s commitment to advancing drug administration technologies. It is meticulously designed to facilitate a rapid onset of action, enhancing patient convenience and compliance. This innovation not only underscores the company’s dedication to leading-edge research and development but also serves as a key differentiator in the competitive pharmaceutical landscape.